Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study

Kan Yonemori, Yasutoshi Kuboki, Kosei Hasegawa, Takashi Iwata, Hidenori Kato, Kazuhiro Takehara, Yasuyuki Hirashima, Hisamori Kato, Chaitali Passey, Jeppe Klint Buchbjerg, Jeffrey R. Harris, Camilla Mondrup Andreassen, Leonardo Nicacio, Ibrahima Soumaoro, Keiichi Fujiwara

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


New treatments, particularly second-line options, are needed to improve outcomes for patients with recurrent/metastatic cervical cancer (r/mCC). Tisotumab vedotin (TV) is an antibody–drug conjugate directed to tissue factor, a transmembrane protein commonly expressed in cancer cells, to deliver cytotoxic monomethyl auristatin E. This single-arm, open-label phase 1/2 trial evaluated the consistency of safety and efficacy outcomes of TV in Japanese patients with r/mCC to bridge the current findings with those reported in previous trials in non-Japanese patients in the United States and Europe. In part 1 (dose escalation; N = 6), patients with advanced solid tumors received TV 1.5 or 2.0 mg/kg once every 3 weeks to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2 (dose expansion; N = 17) evaluated the RP2D in r/mCC patients with 1–2 prior lines of therapy. In part 1, no dose-limiting toxicities were observed, the MTD was not reached, and TV 2.0 mg/kg was established as the RP2D. In part 2, the most common treatment-emergent adverse events were anemia (58.8%), nausea (58.8%), alopecia (47.1%), epistaxis (47.1%), and diarrhea (35.3%); adverse events of special interest were bleeding (76.5%), ocular events (35.3%), and peripheral neuropathy (17.6%), and were mostly grade 1/2. In part 2, confirmed objective response rate was 29.4%, median duration of response was 7.1 months, and median time to response was 1.2 months. In Japanese patients with r/mCC, TV demonstrated a manageable and tolerable safety, pharmacokinetics, and efficacy profile consistent with that observed in non-Japanese patients.

Original languageEnglish
Pages (from-to)2788-2797
Number of pages10
JournalCancer science
Issue number8
Publication statusPublished - 2022 Aug


  • female
  • recurrence
  • thromboplastin
  • tisotumab vedotin
  • uterine cervical neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study'. Together they form a unique fingerprint.

Cite this